Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report.

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Abstract Text:

Kazuya Takamochi,Kazuya Suzuki,Abul Hasan Muhammad Bashar,Kiyoshige Yajima,Takahiro Mochizuki,Toru Itaya,Kazuhito Funai,

ABSTRACT: INTRODUCTION: Gefitinib is a new molecular-targeted agent for the treatment of patients with advanced non-small cell lung cancer that fail to respond to conventional chemotherapy. Gefitinib is considered to be well tolerated and less toxic compared with conventional cytotoxic drugs. However, interstitial lung disease (ILD) has been reported as a serious adverse effect. The precise management of a gefitinib responder having severe adverse events remains unknown. CASE PRESENTATION: We report the case of gefitinib readministration in a patient with lung adenocarcinoma who had once responded but in whom treatment had to be discontinued owing to gefinitib-related ILD. A dramatic response was achieved both at the time of initial treatment (250 mg/day) and at readministration of gefitinib (125 mg/day). The effectiveness of gefitinib therapy in our patient could be explained in part by the presence of an activating mutation of epidermal growth factor receptor (EGFR) gene, L858R in exon 21, which was identified in the primary tumor. CONCLUSION: A reduced dose of gefitinib might be sufficient for patients having tumors with EGFR gene mutations, and that the currently approved dose may be excessively potent in some of these patients, thus resulting in the onset of adverse events.

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Publishing Authors By Initials

K Takamochi,K Suzuki,AH Bashar,K Yajima,T Mochizuki,T Itaya,K Funai,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of medical case reports

VOLUME: 1

Page Numbers: 138

Journal Abbreviation:

ISSN: 1752-1947

DAY: 17

MONTH: 11

YEAR: 2007

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101293382

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report.

AFFILIATION: First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 435-3192 Japan. ktakamoc@hama-med.ac.jp.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Med Case Reports

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report Related Publications

• Expectant management of severe preeclampsia remote from term: hope for the best, but expect the worst.
• Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report.